Spruce Biosciences, Inc. Restricted Cash
Spruce Biosciences, Inc. (SPRB) had Restricted Cash of $35.00 thousand as of 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2025-04-15
- 2024-12-31: Restricted Cash $35.00K.
- 2023-12-31: Restricted Cash $35.00K.
- 2022-12-31: Restricted Cash $200.00K.
- 2022-06-30: Restricted Cash $216.00K.
| Period end | Restricted Cash | Restricted Cash as first filed |
|---|---|---|
| 2024-12-31 | $35.00K 10-K · filed 2025-04-15 | |
| 2023-12-31 | $35.00K 10-K · filed 2025-04-15 | |
| 2022-12-31 | $200.00K 10-K · filed 2024-03-18 | |
| 2022-06-30 | $216.00K 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $216.00K 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $200.00K 10-K · filed 2023-03-16 | $216.00K 10-K · filed 2022-03-14 |
| 2021-09-30 | $216.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $216.00K 10-Q · filed 2022-08-10 | |
| 2021-03-31 | $216.00K 10-Q · filed 2022-05-11 | |
| 2020-12-31 | $216.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $216.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $216.00K 10-Q · filed 2021-08-10 | |
| 2020-03-31 | $216.00K 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |